uploads/2018/05/ousa-chea-552189-unsplash-1.jpg

BlueBird Bio Stock Jumps over 6% on May 17

By

Updated

Bluebird Bio

BlueBird Bio (BLUE) is a biotechnology company focused on developing gene therapy, cancer immunotherapy, and gene editing for the treatment of serious diseases. On May 17, Bluebird Bio (BLUE) stock jumped over 6.1% to the closing price of $189.30 per share, following positive news.

The above chart shows analysts’ recommendations for Bluebird Bio over the last 12 months. BlueBird Bio stock has risen ~119.9% over the last 12 months and 6.3% year-to-date.

Article continues below advertisement

Recent developments

On May 17, Bluebird Bio announced that the company will present the data from ongoing LentiGlobin clinical studies. The data release will include updated data from the Northstar-2 (HGB-207) study, a Phase 3 study evaluating LentiGlobin in patients with transfusion-dependent β-thalassemia (or TDT), and the HGB-206 study, a Phase 1 study evaluating LentiGlobin in patients with sickle cell disease (or SCD). The oral presentations will be highlighted at the 23rd Congress of the European Hematology Association (or EHA).

On May 16, Bluebird Bio announced that the updated data from CRB-401, an ongoing Phase 1 study evaluating bb2121 in patients with refractory/relapsed multiple myeloma, will be presented at the 2018 American Society of Clinical Oncology Annual Meeting in Chicago. The drug bb2121 is an anti-BCMA CAR T cell therapy developed by BlueBird Bio in collaboration with Celgene (CELG).

Analyst recommendations

On May 18, 20 analysts were tracking Bluebird Bio stock. Six of these analysts recommend a “strong buy,” six analysts recommend a “buy,” seven analysts recommend a “hold,” and one of the analysts recommends a “sell.” Analysts expect 13.7% growth in Bluebird Bio stock over the next 12 months to a target price of $215.29 per share as compared to the closing price of $189.30 per share on May 17.

The consensus rating for Bluebird Bio stands at 2.15, which represents a “strong buy” for long-term growth investors and value investors.

The VanEck Vectors Biotech ETF (BBH) holds 1.3% of its total investments in Bluebird Bio (BLUE), 6.7% in Celgene (CELG), 11.4% in Amgen (AMGN), and 5.6% in Biogen (BIIB).

Check out all the data we have added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!

Advertisement

More From Market Realist